UTHR CEO exercises options, sells 9,500 shares
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock.
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. She exercised 9,500 stock options at an exercise price of $135.42 per share and sold 9,500 common shares in open-market trades around $548–$554 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
Following these transactions, she directly holds 40,513 common shares and also has substantial indirect interests through family trusts, including stock options on 349,192 underlying shares at an exercise price of $135.42 expiring on March 15, 2027.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 9,500 shares ($3.93M approx. pre-tax spread)
Exercise and Sale
16 txns
Insider
ROTHBLATT MARTINE A
Role
Chairperson & CEO
Sold
9,500 shs ($5.22M)
Approx. gross sale proceeds
$5.22M
Approx. exercise cost
$1.29M
Approx. pre-tax spread
$3.93M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 9,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 9,500 | $135.42 | $1.29M |
| Sale | Common Stock | 2,098 | $546.9341 | $1.15M |
| Sale | Common Stock | 1,031 | $548.00 | $565K |
| Sale | Common Stock | 3,354 | $549.0336 | $1.84M |
| Sale | Common Stock | 2,116 | $549.8652 | $1.16M |
| Sale | Common Stock | 329 | $550.7755 | $181K |
| Sale | Common Stock | 131 | $551.8846 | $72K |
| Sale | Common Stock | 135 | $553.3878 | $75K |
| Sale | Common Stock | 306 | $553.9046 | $169K |
| holding | Stock Option | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option — 58,718 contracts (Direct);
Common Stock — 40,513 shares (Direct);
Stock Option — 349,192 contracts (Indirect, By Trust);
Common Stock — 166 shares (Indirect, By Spouse);
Common Stock — 628,049 shares (Indirect, By Trust)
Footnotes (14)
- F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F2. This transaction was executed in multiple trades at prices ranging from $546.43 to $547.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. This transaction was executed in multiple trades at prices ranging from $547.465 to $548.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $548.47 to $549.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $549.47 to $550.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $550.51 to $551.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $551.52 to $552.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $552.59 to $553.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $553.695 to $554.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F10. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F11. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F12. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F13. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F14. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
Key Figures
Shares sold: 9,500 shares
Sale prices: $546–$554 per share
Option exercise price: $135.42 per share
+4 more
7 metrics
Shares sold
9,500 shares
Open-market sales of common stock on July 6, 2026
Sale prices
$546–$554 per share
Weighted-average price ranges from multiple trades on July 6, 2026
Option exercise price
$135.42 per share
Exercise price for 9,500 stock options converted to common stock
Direct holdings after trade
50,013 shares
Common stock directly held following reported transactions
Remaining option exposure
349,192 underlying shares
Stock options in family trust at $135.42, expiring March 15, 2027
Net share change
-9,500 shares
Net of 9,500 shares sold versus shares acquired in exercise
Exercise plan cap
1,734,410 stock options
Maximum options to be exercised under 10b5-1 plan or by Dec. 31, 2026
Key Terms
Rule 10b5-1 trading plan, stock options, weighted average price, family trusts, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"exercise of stock options and sale ... was pursuant to a pre-arranged 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"exercise of stock options and sale of the resulting shares of common stock"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
family trusts financial
"Shares held in family trusts as to which the Reporting Person shares investment power"
open-market sale financial
"Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did UTHR CEO Martine Rothblatt report?
Martine Rothblatt reported exercising 9,500 stock options and selling 9,500 United Therapeutics (UTHR) common shares. The sales were open-market trades executed in multiple transactions at prices around $548–$554 per share, as disclosed in the Form 4 filing.
What is the Rule 10b5-1 trading plan mentioned in the UTHR Form 4?
The filing states the option exercise and share sales were under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Such plans schedule trades in advance, helping insiders transact shares over time without making ad hoc trading decisions.
Were the UTHR CEO’s reported stock sales part of a pre-planned program?
Yes. The Form 4 notes the option exercise and resulting share sales occurred under a pre-arranged Rule 10b5-1 trading plan. This plan continues until either 1,734,410 stock options are exercised or December 31, 2026, whichever occurs first.
AI-generated analysis. How Rhea-AI works. Not financial advice.
